OCULAR THERAPEUTIX

Ocular Therapeutix is a biopharmaceutical company leveraging its formulation expertise to develop transformational drug treatments that enhance people's lives... Ocular Therapeutix's first commercial drug product, DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix's earlier stage development assets currently in Phase 1 clinical trials include OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases and OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. In addition to OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease, Ocular Therapeutix is currently evaluating OTX-DED (dexamethasone intracanalicular insert) for the..

Also known as: Ocular Therapeutix, Inc.

Primary location: Bedford United States